June 11 (Reuters) - Kardigan is targeting a valuation of up

to $1.4 billion in its initial public offering in the United

States, the drug developer said on Thursday.

The clinical-stage ​biotech, which is developing precision

medicines for ​cardiovascular diseases, is seeking to raise up

to $373.3 million by offering 23.3 million shares priced between

$14 and $16 each.

The company is advancing three late-stage experimental

therapies: danicamtiv ‌for ⁠genetic dilated cardiomyopathy,

ataciguat for calcific aortic valve stenosis, and tonlamarsen

targeting hepatic angiotensinogen for blood pressure management

in acute severe hypertension.

The Princeton, New Jersey-based company will list on the

Nasdaq under the ⁠ticker ​symbol "KARD".

J.P. Morgan, Jefferies, Leerink Partners ​and TD Cowen are

the underwriters for the offering.